Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov 16;11(1):100.
doi: 10.1186/s40164-022-00353-3.

Neoantigen-specific TCR-T cell-based immunotherapy for acute myeloid leukemia

Weijun Zhou  1   2 , Jinyi Yu  2 , Yilu Li  2 , Kankan Wang  3
Affiliations
Review

Neoantigen-specific TCR-T cell-based immunotherapy for acute myeloid leukemia

Weijun Zhou et al. Exp Hematol Oncol. .

Abstract

Neoantigens derived from non-synonymous somatic mutations are restricted to malignant cells and are thus considered ideal targets for T cell receptor (TCR)-based immunotherapy. Adoptive transfer of T cells bearing neoantigen-specific TCRs exhibits the ability to preferentially target tumor cells while remaining harmless to normal cells. High-avidity TCRs specific for neoantigens expressed on AML cells have been identified in vitro and verified using xenograft mouse models. Preclinical studies of these neoantigen-specific TCR-T cells are underway and offer great promise as safe and effective therapies. Additionally, TCR-based immunotherapies targeting tumor-associated antigens are used in early-phase clinical trials for the treatment of AML and show encouraging anti-leukemic effects. These clinical experiences support the application of TCR-T cells that are specifically designed to recognize neoantigens. In this review, we will provide a detailed profile of verified neoantigens in AML, describe the strategies to identify neoantigen-specific TCRs, and discuss the potential of neoantigen-specific T-cell-based immunotherapy in AML.

PubMed Disclaimer

Conflict of interest statement

All other authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Overview of the procedure for identifying neoantigen-specific TCRs from healthy donors
Fig. 2
Fig. 2
Overview of the neoantigen-specific TCR-based ACT process
See this image and copyright information in PMC

References

    1. Passweg JR, Baldomero H, Chabannon C, Basak GW, de la Camara R, Corbacioglu S, Dolstra H, Duarte R, Glass B, Greco R, Lankester AC, Mohty M, Peffault DLR, Snowden JA, Yakoub-Agha I, Kroger N. Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years. Bone Marrow Transplant. 2021;56:1651–1664. - PMC - PubMed
    1. Xu LP, Wu DP, Han MZ, Huang H, Liu QF, Liu DH, Sun ZM, Xia LH, Chen J, Wang HX, Wang C, Li CF, Lai YR, Wang JM, Zhou DB, Chen H, Song YP, Liu T, Liu KY, Huang XJ. A review of hematopoietic cell transplantation in China: data and trends during 2008–2016. Bone Marrow Transplant. 2017;52:1512–1518. - PubMed
    1. Sweeney C, Vyas P. The Graft-Versus-Leukemia Effect in AML. Front Oncol. 2019;9:1217. - PMC - PubMed
    1. He X, Feng Z, Ma J, Ling S, Cao Y, Gurung B, Wu Y, Katona BW, O'Dwyer KP, Siegel DL, June CH, Hua X. Bispecific and split CAR T cells targeting CD13 and TIM3 eradicate acute myeloid leukemia. Blood. 2020;135:713–723. - PMC - PubMed
    1. Myburgh R, Kiefer JD, Russkamp NF, Magnani CF, Nunez N, Simonis A, Pfister S, Wilk CM, McHugh D, Friemel J, Muller AM, Becher B, Munz C, van den Broek M, Neri D, Manz MG. Anti-human CD117 CAR T-cells efficiently eliminate healthy and malignant CD117-expressing hematopoietic cells. Leukemia. 2020;34:2688–2703. - PubMed

LinkOut - more resources